全文获取类型
收费全文 | 3005篇 |
免费 | 208篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 118篇 |
妇产科学 | 55篇 |
基础医学 | 436篇 |
口腔科学 | 63篇 |
临床医学 | 211篇 |
内科学 | 761篇 |
皮肤病学 | 61篇 |
神经病学 | 166篇 |
特种医学 | 465篇 |
外科学 | 350篇 |
综合类 | 44篇 |
预防医学 | 141篇 |
眼科学 | 34篇 |
药学 | 125篇 |
1篇 | |
中国医学 | 2篇 |
肿瘤学 | 168篇 |
出版年
2023年 | 14篇 |
2022年 | 9篇 |
2021年 | 48篇 |
2020年 | 28篇 |
2019年 | 45篇 |
2018年 | 74篇 |
2017年 | 57篇 |
2016年 | 57篇 |
2015年 | 59篇 |
2014年 | 86篇 |
2013年 | 108篇 |
2012年 | 135篇 |
2011年 | 136篇 |
2010年 | 98篇 |
2009年 | 114篇 |
2008年 | 133篇 |
2007年 | 129篇 |
2006年 | 106篇 |
2005年 | 92篇 |
2004年 | 81篇 |
2003年 | 85篇 |
2002年 | 76篇 |
2001年 | 67篇 |
2000年 | 68篇 |
1999年 | 55篇 |
1998年 | 94篇 |
1997年 | 95篇 |
1996年 | 89篇 |
1995年 | 73篇 |
1994年 | 49篇 |
1993年 | 78篇 |
1992年 | 36篇 |
1991年 | 37篇 |
1990年 | 41篇 |
1989年 | 67篇 |
1988年 | 60篇 |
1987年 | 60篇 |
1986年 | 70篇 |
1985年 | 79篇 |
1984年 | 44篇 |
1983年 | 37篇 |
1982年 | 28篇 |
1981年 | 36篇 |
1980年 | 39篇 |
1979年 | 7篇 |
1978年 | 22篇 |
1977年 | 27篇 |
1976年 | 25篇 |
1975年 | 27篇 |
1969年 | 5篇 |
排序方式: 共有3218条查询结果,搜索用时 15 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
3.
A Espinosa de los Monteros G Roussel N M Neskovic J L Nussbaum 《Journal of neuroscience research》1988,19(2):202-211
A new chemically defined medium consisting of equal parts of Dulbecco modified Eagle's and Ham's F-12 media supplemented with insulin, sodium selenite, putrescine, and D+ galactose, which allows the long-term survival of mature oligodendrocyte pure cultures, is described. Immunohistochemical staining has shown that over 90% of the cells become positive for myelin proteins shortly following subculture. Contaminating astrocytes (2%) do not survive in this medium. Biochemical data have indicated that these purified oligodendrocytes express 2'3'-cyclic nucleotide 3'-phosphohydrolase and UDP-galactose ceramide galactosyltransferase activities. Electron microscopical examination revealed that the oligodendrocytes were mostly of medium-dark type and appeared to be identical to cells cultured in serum-containing medium. The ability to maintain pure oligodendrocyte cultures in such a defined medium will allow investigations concerning exogenous and endogenous factors involved in oligodendrocyte metabolism. 相似文献
4.
5.
RA O. Hempel 《Notfall & Rettungsmedizin》2007,10(5):367-371
Legal uncertainties for emergency vehicle drivers can be avoided when fundamental rules are established. In particular, differentiation of special rights and rights of way is essential. Inherent in both is the urgency necessary to save human lives. The right of way signaled by flashing blue lights and siren does not however justify traffic violations but signifies rather a request to other traffic participants. In contrast, special rights require no announcement and constitute a justifiable reason for traffic violations. Even so they do not allow that other traffic participants be endangered or harmed. Adherence to these basic principles can prevent legal misinterpretations as well as rigid adoption of inflexible standards of behavior. 相似文献
6.
RA Mag. Dr. C. Gepart 《Notfall & Rettungsmedizin》2007,10(4):289-292
Austria’s new Living Wills Act (Patientenverfügungsgesetz, or PatVG) that came into effect on 1st of June 2006, is the first law in Austria to regulate the controversial issue of living wills. The PatVG provides for a right to refuse future medical treatment by making an advance directive in the form of a living will that is either binding or “to be taken into consideration”. However, the establishment of a binding living will is governed by strict criteria as regards form and content, and both a medical doctor and a legal expert must be involved. Compliance with a living will is not allowed where there is a legal obligation to give medical treatment. There is also a legal obligation to give medical treatment in emergency situations where the time involved in looking for a living will could seriously endanger the health or the life of a patient. 相似文献
7.
A Parra F Gabi?o A Ramírez H Valencia I Coria A Espinosa de los Monteros 《Contraception》1991,44(5):541-547
The study was undertaken to analyze the basal and metoclopramide-stimulated serum PRL levels in healthy parous women users (group 1, n = 12) and non-users (group 2, n = 12) of a TCu-380 IUD. All women had regular menses and were studied between days 18 to 22 of their cycle; none had lactated nor regularly ingested any type of medication during the last six months. After a 10-12 hour overnight fast, peripheral venous blood samples were obtained through an indwelling catheter at -30, -15 and 0 minutes and at 60, 90 and 120 minutes after oral metoclopramide (10 mg). There were no significant differences in serum PRL between both groups, in basal levels nor throughout the test, whether analyzing the mean values at each sampling time, the sum of PRL levels from 60-120 minutes, or the peak levels. No correlation was observed between PRL levels and any of the clinical or obstetric characteristics of the women in both groups. Serum progesterone was greater than or equal to 4.0 ng/ml in all women. Thus, the use of alpha TCu-380 IUD did not induce any significant changes in basal nor in stimulated serum PRL levels. 相似文献
8.
Ohne Zusammenfassung 相似文献
9.
Both cyproterone acetate (CPA) and the gonadotrophin-releasing hormone
agonist (GnRHa) have been shown to be effective for the treatment of
hirsutism. We wished to compare the effectiveness of CPA in two standard
doses with GnRHa and add-back therapy and to compare the length of
remission after these treatments. A total of 60 hirsute hyperandrogenic
women was assigned to the following treatment groups: CPA 2 mg with 35
microg of ethinylestradiol for 21 days each month (Diane group), CPA 50 mg,
days 5-15, and ethinylestradiol 50 microg, days 5-25, each month (CPA
group) or Decapeptyl 3.75 mg i.m. every 28 days with the addition of
conjugated oestrogen 0.625 mg, days 1-21, and medroxyprogesterone acetate
10 mg, days 12-21 (GnRHa group). Hirsutism was graded by the
Ferriman-Gallwey-Lorenzo (FGL) index and anagen hair shaft diameters and
serum luteinizing hormone (LH) and testosterone were assessed before and
every 3 months during and after treatment. All women were treated for 1
year with 1 year follow-up. At baseline hirsutism and endocrine patterns
were similar in all groups. After one year of treatment, hirsutism
decreased in all groups but the changes were greater (P <0.05) in the
CPA and GnRHa groups than in the Diane group. Serum LH and testosterone
were lowest in the GnRHa group. After withdrawal, hirsutism increased
rapidly in the Diane and CPA groups and after 6 months, FGL scores and hair
shaft diameters were similar to pretreatment values. In the GnRHa group,
hirsutism increased more gradually and after 1 year of withdrawal, FGL
scores and hair diameters were significantly (P <0.05) less than
pretreatment values. Serum LH and testosterone increased rapidly in all
three groups reaching pretreatment values by 6 months. These data suggest
equal efficacy of the GnRHa and the high dose CPA regimen for the treatment
of hirsutism in hyperandrogenic women. GnRHa with add-back treatment
appears to result in a longer remission of hirsutism in comparison with
CPA.
相似文献
10.